BioPharmX (BPMX) Misses Q4 EPS by 1c
Tweet
Share
E-mailGet Alerts BPMX Hot Sheet
Join SI Premium – FREE
BioPharmX (NYSE: BPMX) reported Q4 EPS of ($0.18), $0.01 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $35 thousand versus the consensus estimate of $40 thousand.
For earnings history and earnings-related data on BioPharmX (BPMX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- Revelation Biosciences (REVB) Misses Q2 EPS by 4c
- bioAffinity (BIAF) Tops Q2 EPS by 146c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
